Correspondence 0001193125-23-215022 from Orchard Therapeutics plc (CIK 0001748907)
Orchard Therapeutics plc (CIK 0001748907)
Date: Aug. 17, 2023 · CIK: 0001748907 · Accession: 0001193125-23-215022
AI Filing Summary & Sentiment
File numbers found in text: 333-273891
Letter
Orchard Therapeutics plc
245 Hammersmith Road
London W6 8PW
United Kingdom
August 17, 2023
Via EDGAR Transmission
United States Securities and Exchange Commission
Division of Corporation Finance
F Street, N.E.
Washington, D.C. 20549
Re: Orchard Therapeutics plc: Registration Statement on Form S-3, filed August 10, 2023 (File No. 333-273891)
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Orchard Therapeutics plc (the “Company”) hereby requests that the effective date of the above-referenced registration statement, as amended (the “Registration Statement”) be accelerated to August 21, 2023, at 4:01 p.m. Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
If you have any questions regarding this request, please contact Catherine Magazu of Goodwin Procter LLP at (617) 570-8274.
Sincerely,
Orchard Therapeutics plc
Show Raw Text
CORRESP 1 filename1.htm CORRESP Orchard Therapeutics plc 245 Hammersmith Road London W6 8PW United Kingdom August 17, 2023 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Orchard Therapeutics plc: Registration Statement on Form S-3, filed August 10, 2023 (File No. 333-273891) Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Orchard Therapeutics plc (the “Company”) hereby requests that the effective date of the above-referenced registration statement, as amended (the “Registration Statement”) be accelerated to August 21, 2023, at 4:01 p.m. Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act. If you have any questions regarding this request, please contact Catherine Magazu of Goodwin Procter LLP at (617) 570-8274. Sincerely, Orchard Therapeutics plc /s/ Frank E. Thomas Frank E. Thomas President and Chief Operating Officer cc: Bobby Gaspar, M.D., Ph.D., Chief Executive Officer, Orchard Therapeutics plc Christopher York, Corporate Counsel, Orchard Therapeutics plc